144,530 members

Skip to content. | Skip to navigation

News

New treatment for adults with chronic lymphocytic leukaemia

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

New treatment for adults with chronic lymphocytic leukaemia

NICE is recommending venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia. Thousands of patients should benefit, NICE says.

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia, with approximately 3,500 new cases diagnosed each year in the UK.

People will be able to access venetoclax plus rituximab from this month, just four months after marketing authorisation was granted in October 2018. Since April 2016 new arrangements with the cancer drugs fund mean NICE aims to publish final guidance within 90 days of licence. More….